Patent ID: 7300917
Filing Date: 2007-11-27
Classification: A61K,A61P,C07C,C07D

Abstract:
1. A pharmaceutical composition comprising an EDG-2 antagonist in combination with one or more selected from LPA receptor antagonist, anti-androgenergic agent, α1 receptor blocker or 5α-reductase inhibitor, wherein the EDG-2 antagonist is a β-alanine derivative of formula (I) wherein A Cyc1 R R R R R R E R R R ia is 0 or an integer of 1 to 5, ma is 0 or an integer of 1 to 4, and na is 0 or an integer of 1 to 4, pa is 0 or an integer of 1 to 5, and wherein when ia is 2 or more, R when ma is 2 or more, R when na is 2 or more, R when pa is 2 or more, they are the same or different, or a prodrug thereof or a salt thereof.